Abstract
A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nat Rev Drug Discov 7, 961–962 (2008). https://doi.org/10.1038/nrd2775
Issue date:
DOI: https://doi.org/10.1038/nrd2775
This article is cited by
-
Nanoplatform based on GSH-responsive mesoporous silica nanoparticles for cancer therapy and mitochondrial targeted imaging
Microchimica Acta (2021)
-
Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis
Current Hypertension Reports (2020)
-
Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance
Endocrine (2017)
-
Discovery of new lead pyrimidines derivatives as potential cannabinoid CB1 receptor antagonistic through molecular modeling and pharmacophore approach
Medicinal Chemistry Research (2014)
-
Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral‐Antagonist/Inverse‐Agonist Therapies
Obesity (2011)
